Triple negative spread to liver - Trodelvy

Hi Bill,  I'm so sorry to hear that.  It's something that all of us here live with - the fear is there from initial diagnosis so we do understand a little how terrible it must feel:((

What treatment is being suggested at the moment? Have you looked away the COC treatment option as well as standard treatments? I see that Trodelvy is licensed in the EU and is being trialled in the UK: it might be worth contacting them. Id they can't help they might know other hospitals near you who are starting to use it

https://www.enherts-tr.nhs.uk/news/mount-vernon-cancer-centre-first-in-uk-to-offer-new-treatment-for-triple-negative-breast-cancer/

https://www.scottishmedicines.org.uk/medicines-advice/sacituzumab-govitecan-trodelvy-full-smc2446/

And discussed in a few weeks in Scotland. 

They are suggesting immunotherapy. But we are still waiting to hear back from tests and whether any clinical trials might be available. Our son is only 7 so I was hoping some extra time could help him build a few more momeries of his mum.

Fingers crossed they start something soon, and I'm so sorry. 

Thanks. Just to update for anyone else waiting, I found this:

NHS England and NHS Improvement and the National Institute for Health and Care Excellence (NICE) have agreed principles to allow potential interim access to medicines licensed through Project Orbis, where there is a gap between licensing and publication of NICE’s guidance. NHS England and NHS Improvement are continuing discussions with Gilead, to urge the company to support interim access arrangements in line with the agreed principles. NICE expects to issue draft guidance on Trodelvy in spring 2022 with final guidance in June 2022.

And received this:

In terms of the triple negative breast cancer drug Trodelvy, we are expecting a decision about its use on the NHS by the SMC in March and NICE in April/May. However, a key thing to note is that eligible patients can currently access the drug ahead of these decisions via what’s called a pre-reimbursement access scheme run by the drug company (Gilead).

Thank you for the information. As at this moment it is approved in Scotland and rejected in England on cost grounds but subject to appeal. My Wife is receiving the treatment anyway via patient access however.